A recent development in how patient requests for experimental drugs are handled could be a big step in health care, said Amrit Ray, chief medical officer for Johnson & Johnson's pharmaceuticals division, Janssen.
On Thursday Johnson & Johnson announced a partnership that enlists the help of an independent third party to review these compassionate use cases. A committee of 10 at the NYU School of Medicine will review patient requests for experimental drugs. This partnership is the first of its kind.
"This comes at a great time because we see a lot of innovation in science and this offers great potential for patients with breakthrough medications," Ray told CNBC's "Power Lunch" on Thursday.